Systems and methods for exploiting near-field impedance and admittance for use with implantable medical devices

• US 8,812,093 B2
• Filed: 01/14/2011
• Issued: 08/19/2014
• Est. Priority Date: 08/09/2010
• Status: Active Grant

• Current Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Inventors: Gutfinger, Dan E., Qu, Fujian, Soriano, Alex, Rooke, Ryan, Nabutovsky, Yelena, Shah, Riddhi
• Primary Examiner(s): Layno, Carl H
• Assistant Examiner(s): Wu, Eugene
• Application Number:
  US13/007,424
• Publication Number:
  US 20120035495A1
• Time in Patent Office: 1,313 Days
• Field of Search: 600/508, 600/509, 600/512, 600/513, 607/24, 607/28
• US Class Current: 600/513
• CPC Class Codes: A61B 5/02 Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
• CPC Class Codes: A61B 5/053 Measuring electrical impedance or conductance of a portion of the body
• CPC Class Codes: A61B 5/0538 invasively, e.g. using a catheter
• CPC Class Codes: A61B 5/341 Vectorcardiography [VCG]
• CPC Class Codes: A61B 5/349 Detecting specific parameters of the electrocardiograph cycle
• CPC Class Codes: A61B 5/686 Permanently implanted devices, e.g. pacemakers, other stimulators, biochips A61B5/6861 takes precedence
• CPC Class Codes: A61N 1/36521 the parameter being derived from measurement of an electrical impedance

Abstract

Various techniques are provided for use with an implantable medical device for exploiting near-field impedance/admittance. Examples include techniques for assessing heart chamber disequilibrium, detecting chamber volumes and pressures, calibrating near-field-based left atrial pressure (LAP) estimation procedures and for assessing the recovery from injury at the electrode-tissue interface. In one particular example, the implantable device assesses the degree of concordance between the left ventricle (LV) and the right ventricle (RV) by quantifying a degree of scatter between LV and RV near-field admittance values. An increase in RV admittance is indicative of RV failure, an increase in LV admittance is indicative of LV failure, and an increase in both LV and RV admittance is indicative of biventricular failure.

Claims

1. A method for use with an implantable medical device for implant within a patient, the method comprising:

detecting vector-based immittance measurements within tissues of the patient using a plurality of electrodes coupled to the device;

converting the vector-based immittance measurements to individual electrode-based immittance values, wherein the individual electrode-based immittance measurements are relative near-field immittance values;

detecting one or more cardiac parameters based on the individual electrode-based immittance values, wherein detecting one or more cardiac parameters includes detecting cardiac parameters representative of disequilibrium among the chambers of the heart from the near-field immittance values; and

controlling at least one device function in response to the parameters.

2. The method of claim 1 wherein the relative near-field immittance values are representative of the immittance of tissues in sufficiently close proximity to the electrode to exclude substantially all far-field immittance contributions.

3. The method of claim 1 wherein detecting parameters representative of disequilibrium among the chambers of the heart includes:

acquiring relative near-field immittance values from the individual electrode-based immittance values corresponding to chambers of the heart;

converting near-field immittance values to relative near-field admittance values;

assessing a degree of concordance between the relative near-field admittance values; and

identifying a poor degree of concordance as being indicative of disequilibrium between the heart chambers.

4. The method of claim 3 wherein assessing a degree of concordance between the relative near-field field admittance values is performed to assess the degree of concordance between the left ventricle (LV) and the right ventricle (RV) by quantifying characteristics of scatter between near-field LV field admittance values and near-field RV field admittance values.

5. The method of claim 4 wherein an increase in RV near-field admittance is indicative of RV failure, an increase in LV near-field field admittance is indicative of LV failure, and an increase in both LV and RV near-field field admittance is indicative of biventricular failure.

6. The method of claim 1 wherein controlling at least one device function in response to the detected parameters includes one or more of:

recording information representative of disequilibrium;

generating warnings representative of disequilibrium; and

controlling cardioelectric stimulation based on disequilibrium.

7. The method of claim 1 wherein detecting parameters includes detecting cardiac parameters representative of one or more of chamber pressure and chamber volume from the near-field immittance values.

8. The method of claim 7 further comprising:

estimating one or more of chamber volume and pressure, wherein estimating one or more of chamber volume and pressure includes estimating one or more of LV end diastolic volume (LV EDV), LV end systolic volume (LV ESV) and left atrial pressure (LAP) from the near-field immittance values.

9. The method of claim 8 wherein estimating LV volume includes calibrating the LV volume estimates using one or more of echocardiography, catheter-based calibration and sensor-based calibration.

10. The method of claim 8 wherein estimating LV EDV includes:

converting the near-field immittance values corresponding to the LVring electrode into corresponding near-field admittance values;

tracking the near-field admittance values over at least one cardiac cycle to identify a maximum near-field admittance; and

identifying the maximum near-field admittance as corresponding to LV EDV.

11. The method of claim 10 wherein estimating LV ESV includes:

converting the near-field immittance values corresponding to the LVring electrode into corresponding near-field admittance values;

tracking the near-field admittance values over at least one cardiac cycle to identify a minimum near-field admittance; and

identifying the minimum near-field admittance as corresponding to LV ESV.

12. The method of claim 11 further including estimating left atrial pressure (LAP) based on LV EDV using an exponential conversion formula.

13. The method of claim 12 wherein the exponential conversion formula is expressed as a*e^kx where a and k are constants and wherein x represents LV EDV.

14. The method of claim 1 further comprising:

preliminarily calibrating estimation of LAP; and

estimating LAP from the near-field immittance values.

15. The method of claim 14 wherein calibrating the estimation of LAP from near-field immittance values includes acquiring pulmonary capillary wedge pressure (PCWP) measurements along with immittance measurements under various physiological conditions, along various vectors, and under different filling pressures, postures and levels of activity and calibrating the estimation procedure based on the measurements.

16. The method of claim 15 wherein calibrating the estimation of LAP from near-field immittance values includes determining calibration coefficients for estimating an RV LAP value from the near-field immittance measurements of at least one RV electrode and for estimating an LV LAP value from the near-field immittance measurements of at least one LV electrode.

17. The method of claim 16 further including acquiring trend data over time for RV LAP corresponding to LAP estimates without time lag.

18. The method of claim 17 further including acquiring trend data over time for LV LAP corresponding to myocardial status with a time lag.

19. The method of claim 15 wherein calibrating the estimation of LAP from near-field immittance values includes determining calibration coefficients for estimating an RV LAP value from the near-field immittance measurements of at least one RV electrode and for estimating an LV LAP value by converting LV near-field immittance values into equivalent RV near-field immittance values and applying calibration coefficients for RV LAP to derive LV LAP.

20. The method of claim 15 wherein calibrating the estimation of LAP from near-field immittance values includes determining calibration coefficients for estimating an LV LAP value from the near-field immittance measurements obtained in the supine posture of at least one LV electrode and for estimating an LV LAP value by converting LV near-field immittance values obtained in the upright standing posture into equivalent supine LV near-field immittance values and applying calibration coefficients to derive LV LAP.

21. The method of claim 1 wherein detecting parameters includes assessing an electrode-tissue interface based on near-field immittance measurements.

22. The method of claim 21 wherein assessing the electrode-tissue interface based on near-field immittance measurements includes determining a representative baseline reference near-field immittance.

23. The method of claim 22 including assessing a recovery pattern of tissue injury at the electrode-tissue interface based on a recovery of the near-field immittance relative to the representative baseline reference near-field immittance.

24. The method of claim 22 wherein assessing the electrode-tissue interface based on near-field immittance measurements includes assessing a recovery of myocardial wall edema and one or more of the cardiac chamber volumes following an episode of heart failure decompensation.

25. The method of claim 22 wherein assessing electrode-tissue interface based on near-field immittance measurements includes detecting a significant physical disturbance.

26. The method of claim 25 wherein the significant physical disturbance includes one or more of lead dislodgement, perforation, infection, and lead failure.

27. A system for use with an implantable medical device for implant within a patient, the system comprising:

a vector-based detector operative to detect vector-based immittance measurements within tissues of the patient using a plurality of electrodes coupled to the device;

a converter operative to convert the vector-based immittance measurements to individual electrode-based immittance values, wherein the individual electrode-based immittance measurements are relative near-field immittance values;

a detector operative to detect one or more cardiac parameters based on the individual electrode-based immittance values, wherein the detector detects cardiac parameters representative of disequilibrium among the chambers of the heart from the near-field immittance values; and

a controller operative to control at least one device function in response to the detection of disequilibrium.

28. A system for use with an implantable medical device for implant within a patient, the system comprising:

means for detecting vector-based immittance measurements within tissues of the patient using a plurality of electrodes coupled to the device;

means for converting the vector-based immittance measurements to individual electrode-based immittance values, wherein the individual electrode-based immittance measurements are relative near-field immittance values; and

means for detecting one or more cardiac parameters based on the individual electrode-based immittance values, wherein the means for detecting detects cardiac parameters representative of disequilibrium among the chambers of the heart from the near-field immittance values.